Your new post is loading...
Your new post is loading...
Researchers discover new target for vaccine development in abundant immune ...Medical XpressResearchers evaluated healthy human tissues key to the immune system to assess the abundance of neutrophils in the lymph nodes, tonsils, lymphoid tissue in...
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagno...
SAN DIEGO, CA -- (Marketwire) -- 07/24/12 -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,226,949 providing broad protection for stabilized formulations of monoclonal antibodies.
Damaged and aged heart tissue of older heart failure patients was rejuvenated by stem cells modified by scientists, according to research presented at the Ameri (RT @AGE: New stem cell therapy succesfully rejuvenates aging heart muscle cells in humans.)...
Conditions : Neuroblastoma; Melanoma; Osteosarcoma Intervention : Biological: Anti-G2 antibody Sponsors : St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Evan T. J. Dunbar Neuroblastoma Foundation, Inc.;...
In this Eureka Podcast Episode, Shawna Jackman, Senior Research Scientist at Charles River, provides her top 10 tips to consider when designing a translational cell therapy preclinical program.
ODYSSEY, a global program to evaluate SAR236553 REGN727, a potential first-in-class PCSK9 inhibitor, will comprise over ten clinical trials and will include mor (Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering...
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute My...
T-cell therapy with Transplant in Treating High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma - CITY OF HOPE http://t.co/6sbVbYD5...
RT @celltherapy: We are tracking 47 industry-sponsored pivotal, ph 3 or 2/3 cell therapy trials involving >11,000 patients http://t.co/tu1F6yxu...
Johns Hopkins tissue engineers have used tiny, artificial fiber scaffolds thousands of times smaller than a human hair to help coax stem cells into developing into cartilage, the shock-absorbing lining of elbows and knees that ...
|
20000000. This is the number of peripheral artery disease patients Pluristem Therapeutics, a placenta-based cell therapy company, is working to assist. The company recently released information regarding the effectiveness of cell therapy ...
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recur http://t.co/KEVBD7kb...
Free Article: Intraspinal Stem Cell Transplantation. leave a comment ». Background: No United States-based clinical trials have attempted delivery of biological therapies directly to the spinal cord for treatment of amyotrophic ...
DGAP-News: SuppreMol GmbH / Key word(s): StudySuppreMol GmbH: SuppreMol begins development of Anti-IL-3 monoclonalantibody to diagnose and treat early stage Rheumatoid Arthritis24.07.2012 /...
Antibody therapy may stabilize early Alzheimer’s symptoms > Facts & Fears > ACSH via @rosie_ms: Antibody therapy may...
CytoDyn (Other OTC:CYDY.PK - News) is a development stage biotech company focused on the discovery and development of novel anti-HIV and anti-FIV agents. The Company holds two proprietary platform technologies: Cytolin, a ...
Biotest’s Antibody-drug Conjugate BT-062 In Multiple Myeloma Combination Therapy (#clinicaltrials Biotest’s Antibody-drug Conjugate BT-062 In Multiple Myeloma Combination Therapy: BT-062, an ant...)...
Background: No United States-based clinical trials have attempted delivery of biological therapies directly to the spinal cord for treatment of amyotrophic lateral sclerosis (ALS) because of the lack of a meaningful US Food and Drug...
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Prev...
Introductions: Although randomized clinical trials showed no benefit from combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with standard chemotherapy for advanced non–small-cell lung cancer (NSCLC), better results...
Correspondence from The New England Journal of Medicine — Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis (RT @JuanCIvancevich: Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis — NEJM
Penn Medicine is building a war chest of approaches to enhance the ability of T cells to attack as many cancer types as possible.
|